<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Introduction: Among <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancers</z:e>, colorectal and gastric <z:hpo ids='HP_0002664'>neoplasms</z:hpo> are the most frequent </plain></SENT>
<SENT sid="1" pm="."><plain>The development of new targeted drugs improved the efficacy of systemic therapy in advanced stages of those <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Areas covered: This review highlights the main biological processes implicated in <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> development and progression, such as <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and epidermal growth factor receptor (EGFR) signaling pathway </plain></SENT>
<SENT sid="3" pm="."><plain>On these bases, anti-EGFR and anti-vascular endothelial growth factor (VEGF) monoclonal antibodies in colorectal and <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> are discussed </plain></SENT>
<SENT sid="4" pm="."><plain>Data about further monoclonal antibodies in development are also reported </plain></SENT>
<SENT sid="5" pm="."><plain>Expert opinion: The use of monoclonal antibodies in colorectal and <z:hpo ids='HP_0012126'>gastric cancers</z:hpo> showed the best outcomes when combined with chemotherapy, even though single agent anti-EGFR antibodies seem active in particular setting of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients </plain></SENT>
<SENT sid="6" pm="."><plain>It is not well defined whether the addition of anti-VEGF and anti-EGFR to chemotherapy could improve outcome in those patients susceptible to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-related <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> resection </plain></SENT>
<SENT sid="7" pm="."><plain>Little and conflicting data are available about the role of these drugs in adjuvant setting </plain></SENT>
<SENT sid="8" pm="."><plain>Tests are available to select patients with higher probability to get benefit from these treatments </plain></SENT>
<SENT sid="9" pm="."><plain>Further biomarkers need to be evaluated to improve this selection and achieve "tailorization" of systemic therapy </plain></SENT>
</text></document>